The Oxylipin Response as a New PrEdictive Biomarker of Patient Responsiveness to Biotherapy in Rheumatoid Arthritis (OPERA)
NCT05552105
·
clinicaltrials.gov ↗
NA
Phase
COMPLETED
Status
30
Enrollment
OTHER
Sponsor class
Conditions
Rheumatoid Arthritis
Interventions
OTHER:
Blood test
Sponsor
University Hospital, Clermont-Ferrand
Collaborators
[object Object]
[object Object]